NIH DP1 funding opportunities: NIH Director's Pioneer Award
3 NIH notices for DP1 (NIH Director's Pioneer Award) are open and 1 forecast. Support for an exceptionally creative scientist's high-risk, high-impact ideas.
- Open notices3
- Forecast1
- Projects funded under them6,616
Open NIH DP1 notices
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
Open - Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
Open - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
Open
Forecast DP1 notices
Institutes that fund DP1 projects under these notices
| Institute or center | Projects |
|---|---|
| National Cancer Institute (NCI) | 982 |
| National Heart Lung and Blood Institute (NHLBI) | 728 |
| National Institute of General Medical Sciences (NIGMS) | 591 |
| National Institute on Aging (NIA) | 581 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 539 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 523 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 468 |
| National Institute on Drug Abuse (NIDA) | 323 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 302 |
| National Institute of Mental Health (NIMH) | 286 |
Closed DP1 notices
- RFA-RM-27-001: NIH Director’s Pioneer Award (DP1 Clinical Trial Optional)
- PAR-23-021: Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
- RFA-RM-25-001: NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
- PAR-25-261: NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
- RFA-DA-24-007: Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)
- RFA-DK-26-006: NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
- PAR-23-024: Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional)
- PA-23-189: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
- PAR-23-269: NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
- RFA-DA-23-026: NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional)
- RFA-DA-23-031: NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional)
- RFA-RM-24-002: NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
- PA-21-268: Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- RFA-DK-23-014: NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
- RFA-RM-23-004: NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
- RFA-RM-22-018: NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
- RFA-DA-23-014: Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)
- RFA-RM-21-015: NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
Questions people ask
What is an NIH DP1?
DP1 is NIH's activity code for the NIH Director's Pioneer Award. Support for an exceptionally creative scientist's high-risk, high-impact ideas. Each notice sets its own budget limit, project length and due dates.
How many NIH DP1 funding opportunities are open?
3 notices are open on Grants.gov, and 1 more is forecast, as of the latest data.